Rexahn Pharmaceuticals, Inc. (NYSE:RNN) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 77.57M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For RNN, the company currently has 8.79 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 28.09 million in total assets, balanced by 12.19 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Rexahn Pharmaceuticals, Inc. (RNN) saw -4.11 million in free cash flow last quarter, representing a quarterly net change in cash of -1.7 million. Perhaps most importantly where cash movements are concerned, the company saw about -4.1 million in net operating cash flow.
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the RNN saw sales decline by 0.00.
But what about the bottom line? After all, that’s what really matters in the end. Rexahn Pharmaceuticals, Inc. (RNN) is intriguing when broken down to its core data. The cost of selling goods last quarter was 11,023, yielding a gross basic income of -11,023 . For shareholders, given the total diluted outstanding shares of 28.27 million, this means overall earnings per share of 0.03.
Is Rexahn Pharmaceuticals, Inc. (NYSE:RNN) Valuation Attractive
We consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Rexahn Pharmaceuticals, Inc..